Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
ApexOnco Front Page
Recent articles
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
NVL-330 features among the latest crop of industry projects newly into human trials.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
The companies hope to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.